Compare W W Grainger Inc (GWW) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Johnson & Johnson — how do they compare? W W Grainger Inc trades at $1,289.35 (market cap $59.76B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 10.3× W W Grainger Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Johnson & Johnson for 129 Days on average.
| GWW | JNJ | |
|---|---|---|
Market Cap | $59.76B | $618.09B |
Volume | 186,697 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $1.40K | $278.43 |
52-Week Low | $918.18 | $186.00 |
Typical Hold Time | 25 Days | 129 Days |
Enterprise Value | $61.96B | $646.37B |
Dividend Yield | 0.79% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,289.79, up 2.08% today, with a bearish technical signal but strong fundamentals including a 47.92% ROE and recent earnings beats. The company reported Q2 2026 EPS of $12.01, beating expectations, and maintains a net income margin of 9.92%. Recent developments include the acquisition of technology assets from Adroit Worldwide Media for $210 million and the opening of a new distribution center in Oregon, supporting growth initiatives.
The outlook is mixed: analyst consensus is a hold with a $1,310 price target, but strong profitability and strategic acquisitions offer upside. Risks include high valuation multiples like a P/E of 32.34 and competitive pressures in industrial distribution. Cash flow trends improved in 2026, with net cash flow near breakeven, reducing liquidity concerns.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
